Released Aug 14, 2019, after the close
10-Q filed Aug 14, 2019, 45 days after period end · 0001390478-19-000045
Q2 2019 · 10-Q
Revenue—
Net Income-$3.13M-$3.13M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$6.33-$6.33 N/M vs Q2 2018N/M vs Q1 2019
Operating Cash Flowderived-$4,656,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Net Income | -$3.13M | -$6.06M | -$5.91M | $5.39M |
| EPS Diluted | -$6.33 | -$1.26 | -$0.22 | $0.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR